<DOC>
	<DOCNO>NCT02689804</DOCNO>
	<brief_summary>A well-designed pharmacokinetics ( PK ) study may identify physiologic basis observe difference levonorgestrel emergency contraception ( LNG-EC ) ulipristal acetate emergency contraception ( UPA-EC ) failure rate woman normal obese BMI . The investigator propose study compare serum LNG UPA level administration single-dose LNG-EC UPA-EC . The investigator hypothesize difference PK parameter woman normal BMI obese woman .</brief_summary>
	<brief_title>EC PK Women With Normal Obese BMI</brief_title>
	<detailed_description>Eligible woman present division research office , time history physical exam complete . Each participant 's BMI confirm assign one two BMI group ( 18.5-24.9 versus 30-39.9 ) . At conclusion enrollment visit , research coordinator randomize woman receive single-dose pill either levonorgestrel 1.5mg ( like Plan B One-Step® generic formulation ) ulipristal acetate 30mg ( ellaOne® ) two separate occasion .</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptives , Postcoital</mesh_term>
	<criteria>Women age 1845 year Englishspeaking BMI 18.524.9 BMI 30.039.9 Regular menstrual cycle No use medroxyprogesterone acetate least 6 month prior study enrollment , unless resumption two menstrual cycle No use levonorgestrel intrauterine system ( levonorgestrelIUS ) , etonogestrel implant combine hormonal contraception least one month prior study resumption one menstrual cycle Women postpartum postabortion include least one menstrual cycle since last pregnancy Prior allergic reaction LNGEC UPAEC Use hormonal emergency contraception within past month Women currently pregnant currently breastfeed History cancer nonmelanoma skin cancer Medical surgical condition condition require therapy know impact sex steroid production metabolism Use HAART therapy management HIV infection Concomitant use CYP3A4 inducer like rifampin , barbiturate , carbamazepine , lamotrigine , bosentan , felbamate , griseofulvin , oxcarbazepine , phenytoin , St. John 's Wort topiramate Current participation trial investigational medicine device three month lead study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Emergency contraception</keyword>
</DOC>